Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The IO Switch: Making Tumor-Associated Macrophages Work In Our Favor

Executive Summary

Emerging Company Profile: Macrophage Pharma is using novel chemistry to deliver therapies directly into tumor-associated macrophages, switching their activity from immunosuppressive to immuno-stimulatory to initiate anti-tumor immune responses.

Advertisement

Related Content

Early Stage Science Watch
Five Prime Enters Transition Phase; Multiple Trials Planned In Next 12 Months
A Quick Primer On Roche's Immuno-Oncology Assets
Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings
Kancera To Pursue Ex-AZ Asset Targeting Fractalkine Into Clinic
VC Roundup: 2016 US Investment Ends On A Down Note, But Biopharma Has Second-Best Year
Sixth Element On Bridging The Divide To Get Drugs To Patients Faster

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel